Clinical Trial Update: ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab

View source ↗

Summary

A registry study in Chinese patients with relapsed and refractory multiple myeloma treated with elranatamab is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• And Refractory Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Peking University People's Hospital | Conditions: TCE-RRMM | Status: NOT_YET_RECRUITING